![](https://endpts.com/wp-content/uploads/2017/09/fda-tile-endpoints-3.jpg)
FDA rejects Acer's rare disease drug, asks for new trial — shares crater
Acer Therapeutics’ bid to repurpose celiprolol — a beta-blocker on the market for hypertension — as a treatment for a rare, inherited connective tissue disorder has hit …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.